Revelle gains extended FDA clearance for cellulite release device

The cellulite release device Avéli has gained extended FDA clearance for long-term reduction in the appearance of cellulite in the buttocks and thigh areas of women, Revelle Aesthetics announced in a press release.

The Avéli device is used in a minimally invasive procedure that allows identification of fibrous septa bands that cause cellulite dimples as well as confirmation in real-time that those targeted septa are being released, according to the release.

“[W]e believe Avéli will play a role as a cornerstone in the latest and fastest growing category in medical aesthetics, lower body rejuvenation,” Caroline Van Hove president and CEO of Revelle Aesthetics, said in the release.